Today's Nasdaq IPO marks new era of biomanufacturing - pioneered by Invizyne's breakthrough...

Dr. Lalonde: From two years and 25 scientists to a few scientists for a few months "When I...

"Invizyne is taking what nature has done and [...] putting things in a manufacturing format so we...

Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL (DoE), states: "What...

NREL (DoE) working with Invizyne in their 'Advancing Clean Tech to Energize the Future' project -...

Commercializing Invizyne’s cell-free platform - fireside chat withZachary Karl, PhD, Vice...

MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a...

In this video, CEO of Invizyne, Michael Heltzen - and VP of Research, Tyler Korman, PhD -...

In this video, CEO of MDB Capital Holdings, Chris Marlett, presents Invizyne. Invizyne is a...